Twice-yearly exam unneceary for patient taking quetiapine

Purpoe To determine the neceity for the heightened level of monitoring for cataract development in patient taking quetiapine (eroquel, AtraZeneca Pharmaceutical, Wilmington, Delaware) dictated by the Phyicianʹ Dek Reference. Alo, to explore the poibility of cataractogenei becaue of quetiapine therapy. Deign Obervational cae erie. Method Data were garnered from a erie of 80 cae report collected at the National Regitry of Drug-Induced Ocular ide Effect (Portland, Oregon). The World Health Organization (WHO) cauality aement guideline were ued to ae the relationhip between quetiapine and cataractogenei. Reult There were 34 report of cataract aociated with quetiapine therapy. Average age wa 44 year with 23 female and 11 male tudied. Average duration of therapy wa 29.3 week on tandard doe. Concluion Cataractogenei econdary to quetiapine i “unlikely” by WHO guideline. Thi probably make it unneceary to require biannual ophthalmic examination a routine eye examination are ufficient to creen for thi condition.